Stockreport

Alexion readies study of Ultomiris in severely ill COVID-19 patients [Seeking Alpha]

Alexion Pharmaceuticals, Inc  (ALXN) 
Last alexion pharmaceuticals, inc earnings: 1/30 06:30 am Check Earnings Report
US:NASDAQ Investor Relations: ir.alexion.com/investor-relations
PDF Alexion Pharmaceuticals (NASDAQ:ALXNannouncesRavulizumab, a C5 complement inhibitor, is approved in the U.S. to treat paroxysmal nocturnal hemoglobinuria and atypical he [Read more]